Small-cell carcinoma

Global Small Cell Lung Cancer Pipeline Analysis 2019: 165 Pipeline Programs in Active Development, 118 Active Companies, Key Players and Deals

Retrieved on: 
Wednesday, October 30, 2019
Cancer, Neoplasms, Clinical medicine, Small-cell carcinoma, Lung cancer, SCLC, Chemotherapy, Combined small-cell lung carcinoma, Targeted therapy of lung cancer

The recent approval of targeted and immuno-therapies for SCLC will generate a new maintenance setting following chemotherapy in SCLC.

Key Points: 
  • The recent approval of targeted and immuno-therapies for SCLC will generate a new maintenance setting following chemotherapy in SCLC.
  • There are 165 pipeline programs in active development for SCLC.
  • Recognize commercial opportunities by identifying first-in-class pipeline programs for SCLC that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class SCLC programs.
  • 2 Small Cell Lung Cancer: Executive Summary

Global Small Cell Lung Cancer Pipeline Report 2019: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 29, 2019
Health, Oncology, Lung cancer, Clinical medicine, Neoplasms, Small-cell carcinoma, Chemotherapy, Cancer, Combined small-cell lung carcinoma, Treatment of lung cancer

The "Frontier Pharma - Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Frontier Pharma - Small Cell Lung Cancer: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease" report has been added to ResearchAndMarkets.com's offering.
  • Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer (SCLC) remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis.
  • The recent approval of targeted and immuno-therapies for SCLC will generate a new maintenance setting following chemotherapy in SCLC.
  • Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology.

IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line Treatment of Stage IV Non-Small Cell Lung Cancer

Retrieved on: 
Monday, October 28, 2019
Pharmaceutical, Health, Oncology, Clinical trials, Cancer, Clinical medicine, Lung cancer, Medicine, Monoclonal antibodies, Durvalumab, Cancer immunotherapy, Non-small-cell lung carcinoma, Small-cell carcinoma, Treatment of lung cancer, Tecemotide, POSEIDON, Stage IV NSCLC, IMFINZI® (durvalumab), tremelimumab, AstraZeneca Support Programs, AstraZeneca in Lung Cancer, AstraZeneca’s Approach to Immuno-Oncology (IO), AstraZeneca in Oncology, AstraZeneca

Jos Baselga, Executive Vice President, Oncology R&D, said: The POSEIDON trial provides evidence of the efficacy of IMFINZI in patients with Stage IV non-small cell lung cancer.

Key Points: 
  • Jos Baselga, Executive Vice President, Oncology R&D, said: The POSEIDON trial provides evidence of the efficacy of IMFINZI in patients with Stage IV non-small cell lung cancer.
  • IMFINZI is also being tested in Stage IV NSCLC as monotherapy in the Phase III PEARL trial, and in earlier stages of disease as part of an extensive Immuno-Oncology program in lung cancer.
  • IMFINZI is approved in the curative-intent setting of unresectable, Stage III NSCLC after concurrent chemoradiation therapy based on the Phase III PACIFIC trial.
  • IMFINZI is indicated for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Tarveda Therapeutics Publishes Results of Preclinical Studies Evaluating PEN-221 as a Treatment for Small Cell Lung Cancer in Molecular Cancer Therapeutics

Retrieved on: 
Thursday, October 24, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Neoplasms, Clinical medicine, Lung cancer, Infectious causes of cancer, Neuroendocrinology, Neuroendocrine tumor, Pancreatic cancer, Endocrine oncology, Somatostatin receptor 2, Small-cell carcinoma, Cancer, Pulmonary neuroendocrine tumor

The publication, Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer , was published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

Key Points: 
  • The publication, Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer , was published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
  • SSTR2 is overexpressed on the surface of cancer cells in patients with a range of solid tumors including SCLC and neuroendocrine cancers.
  • SSTR2 is overexpressed on the cell surface of a range of solid tumors including neuroendocrine tumors and small cell lung cancer.
  • PEN-221 is being evaluated in Phase 2a expansion cohorts currently enrolling patients with midgut neuroendocrine tumors and small cell lung cancer (ClinicalTrials.gov Identifier: NCT02936323 ).

GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells

Retrieved on: 
Tuesday, October 22, 2019
Neoplasms, Clinical medicine, Non-small-cell lung carcinoma, Lung cancer, Cancer, Small-cell carcinoma, Targeted therapy of lung cancer, Combined small-cell lung carcinoma

Jeffrey Miller, Martin Felices and Pippa Kennedy from the University of Minnesota presented research results at the recently concluded 18th meeting of the Society for Natural Immunity concerning a solid tumor targeting TriKE which demonstrates killing of non-small cell lung cancer tumor cells.

Key Points: 
  • Jeffrey Miller, Martin Felices and Pippa Kennedy from the University of Minnesota presented research results at the recently concluded 18th meeting of the Society for Natural Immunity concerning a solid tumor targeting TriKE which demonstrates killing of non-small cell lung cancer tumor cells.
  • According to the American Cancer Society, non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses.
  • Lung cancer is the second most common cancer, and this year it is estimated that 142,670 people will die from lung cancer.
  • TriKE is a trademark of GT Biopharma, Inc.
    Dr. Miller also serves as Consulting Chief Medical Officer of GT Biopharma, Inc.

Growth of Lung Cancer Therapeutics Market to Be Impacted by the Advent of Regenerative Therapies | Technavio

Retrieved on: 
Friday, October 18, 2019
Health, Oncology, Clinical medicine, Medicine, Cancer treatments, Lung cancer, Chemotherapy, Occupational safety and health, Oncology, Fallopian tube, Cancer, Small-cell carcinoma

Browse Related Health Care Reports:

Key Points: 
  • Browse Related Health Care Reports:
    Global Non-small Cell Lung Cancer Drugs Market 2019-2023: The global non-small cell lung cancer drugs market is forecast to grow at a CAGR of over 13% during the period 2019-2023.
  • The non-small cell lung cancer drugs market size will increase by USD 14.28 billion during the forecast period of 2019-2023.
  • Global Fallopian Tube Cancer Therapeutics Market 2019-2023: The global fallopian tube cancer therapeutics market is forecast to grow at a CAGR of over 8% during the period 2019-2023.
  • The fallopian tube cancer therapeutics market size will increase by USD 429.11 million during the forecast period of 2019-2023.

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

Retrieved on: 
Wednesday, October 16, 2019
Cancer, Lung cancer, Clinical medicine, Neoplasms, Cancer treatments, Carcinoma, Cytopathology, RTT, Small-cell carcinoma, Non-small-cell lung carcinoma, Chemotherapy, Combined small-cell lung carcinoma

Management plans to expand its ongoing clinical myelopreservation trial to include two additional cohorts: an expansion cohort in small-cell lung cancer patients and a cohort in non-small-cell lung cancer patients.

Key Points: 
  • Management plans to expand its ongoing clinical myelopreservation trial to include two additional cohorts: an expansion cohort in small-cell lung cancer patients and a cohort in non-small-cell lung cancer patients.
  • Company expects to present key findings of the phase 1b portion of this myelopreservation trial in the 2nd quarter of 2020.
  • Every year, millions of cancer patients undergo chemotherapy with the hope of prolonging their lives or being cured from a deadly disease.
  • Although this first myelopreservation trial for ALRN-6924 is in SCLC patients treated with topotecan, we plan to develop ALRN-6924 as a tumor type-agnostic and chemotherapy-agnostic myelopreservation drug.

Merck’s KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

Retrieved on: 
Wednesday, October 2, 2019
Oncology, Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Cancer, Medicine, Lung cancer, Antineoplastic drugs, Breakthrough therapy, Merck, Pembrolizumab, Non-small-cell lung carcinoma, Small-cell carcinoma, Merkel-cell carcinoma, Melanoma

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.

Key Points: 
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.
  • Selected Indications for KEYTRUDA (pembrolizumab) in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer

Retrieved on: 
Monday, September 30, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Clinical medicine, Medicine, Carcinoma, Atezolizumab, Genentech, Cancer treatments, RTT, Chemotherapy, Transitional cell carcinoma, Transitional epithelium, Cancer, Small-cell carcinoma, the IMvigor130 study, bladder cancer, Tecentriq® (atezolizumab), Genentech in personalized cancer immunotherapy, Genentech

There appeared to be no worsening of tolerability with the addition of Tecentriq to chemotherapy compared with chemotherapy alone.

Key Points: 
  • There appeared to be no worsening of tolerability with the addition of Tecentriq to chemotherapy compared with chemotherapy alone.
  • All cause Grade 3-4 adverse events (AEs) were reported in 85% of people receiving Tecentriq plus chemotherapy compared with 86% of people receiving chemotherapy alone.
  • Treatment-related Grade 3-4 AEs were reported in 83% of people receiving Tecentriq plus chemotherapy compared with 81% of people receiving chemotherapy alone.
  • Tecentriq is a prescription medicine used to treat adults with:
    A type of bladder and urinary tract cancer called urothelial carcinoma.

Opdivo (nivolumab) Demonstrates Statistically Significant Overall Survival Benefit Versus Chemotherapy in Patients with Advanced Esophageal Cancer

Retrieved on: 
Monday, September 30, 2019
Biotechnology, Health, Pharmaceutical, Oncology, Cancer, Clinical medicine, Medicine, Lung cancer, Antineoplastic drugs, Cancer treatments, Breakthrough therapy, Bristol-Myers Squibb, Small-cell carcinoma, Non-small-cell lung carcinoma, Nivolumab, Chemotherapy

An exploratory analysis of patient-reported outcomes showed significant overall improvement in quality of life with Opdivo versus chemotherapy.

Key Points: 
  • An exploratory analysis of patient-reported outcomes showed significant overall improvement in quality of life with Opdivo versus chemotherapy.
  • Seven patients in the Opdivo arm had ongoing responses at data cutoff compared to two patients in the chemotherapy arm.
  • Fewer treatment-related adverse events (TRAEs) were reported with Opdivo versus chemotherapy, with a rate of 66% of any grade TRAEs for patients receiving Opdivo compared to 95% for patients receiving chemotherapy.
  • OPDIVO (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.